Original Article Protective effects of Xiaoerchiqiaoqingre granule on children with acute upper respiratory tract infection

Yuzhen Wang¹, Qizheng Han³, Xinjie Liu^{1,2}

¹Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, China; ²Brain Science Research Institute, Shandong University, Jinan, China; ³Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, China

Received October 31, 2016; Accepted March 30, 2017; Epub September 15, 2017; Published September 30, 2017

Abstract: The aim of this study was to perform a preliminary investigation of the efficacy and safety of Xiaoerchiqiaoqingre granule, a traditional Chinese medicine, on children with acute upper respiratory tract infection. A total of 89 children with acute upper respiratory tract infection were randomly assigned to a Xiaoerchiqiaoqingre granule treatment or a ribavirin treatment. Treatment was given every 8 h for 3 days. Clinical symptoms and adverse events in both groups were assessed and laboratory tests including blood cell count, ESR, CRP, IL-6, TNF- α , liver function and renal function were done at enrolment and then after 72 h. Significantly more children's body temperature in Xiaoerchiqiaoqingre granule group dropped to normal compared to those of control group at 48 h and 72 h following treatment. The intervention group had a higher proportion of children fulfilling the criteria of cure at 48 h as opposed to control group (P<0.05). Significant differences between intervention and control groups were also found in fulfilling the criteria of cure at 72 h (P<0.01). ESR, CRP, IL-6 and TNF- α in children of the two groups increased and a significant decrease of the ESR, CRP, IL-6 and TNF- α in the blood at 72 h posttreatment with Xiaoerchiqiaoqingre granule was recorded compared with those of the control group. There were no obvious side effects in children after treatment with Xiaoerchiqiaoqingre granule. Xiaoerchiqiaoqingre granule is effective and safe to be prescribed in children with acute upper respiratory tract infection.

Keywords: Respiratory tract infection, traditional Chinese medicine, cytokine

Introduction

Respiratory viral infections, characterized by fever, are the most common viral infection in children under 2 years and is a primary cause of their hospitalization worldwide [1-3]. Nearly half of pediatric community acquired pneumonia and a guarter of adult cases have evidence of viral infection [4, 5]. The recurrent outbreaks of the disease potentially bring about severe consequences for human health and global economy. Based on these facts, much attention has consequently been given to the development of antiviral drugs for the prevention and treatment of this disease. However, to date, there is no specific antiviral or anti-inflammatory medication with proven beneficial effect on the course of acute upper respiratory tract infection globally [6-11]. Therefore, effective and safe medication for this disease is still controversial. Although existent evidence tested by randomized trials is sparse and limited, traditional Chinese medicines as natural substances for respiratory virus infection treatment have played an important role in the Far East countries, especially in China, Japan and Korea [12, 13]. Xiaoerchiqiaoqingre granule, whose major ingredients are based composed of fructus forsythiae, semen sojae praeparatum, mint, schizonepeta tenuifolia, gardenia, rheum officinale, artemisinins, radix paeoniae rubra, areca, magnolia officinalis, scutellaria baicalensis, pinellia ternate, radix bupleuri and liquorice, has been widely used as folk medicine for over 300 years and prescribed for more than two decades in China, especially in Shandong province. Nevertheless, there is no reports clarified the protective effects and safety of Xiaoerchigiaogingre granule on acute upper respiratory tract infection in children. Therefore, the objec-

ISTICS			
Characteristic	Control group (n=40) (%)	Trial group (n=49) (%)	P value
Gender			
Male	25 (62.5)	29 (59.18)	0.45
Female	15 (37.5)	20 (40.81)	0.58
Age group			
Up to 1 year	10 (25)	12 (24.50)	0.82
>1-2 years	15 (37.5)	17 (34.69)	0.76
2-6 years	8 (20)	12 (24.50)	0.37
7-14 years	7 (17.5)	8 (16.33)	0.85
Body weight (Kg)	24.5±16.8	24.3±16.5	0.92
Heig ht (cm)	115.2±37.5	113.5±38.6	0.83
Major symptoms			
Cough	29 (72.5)	35 (71.43)	0.86
Nasal discharge	28 (70)	33 (67.35)	0.77
Fever	29 (72.5)	35 (71.43)	0.80
Pharyngitis	32 (80)	38 (77.56)	0.65
Tonsillitis	35 (87.5)	43 (87.76)	0.88

 Table 1. Patient demographic and clinical characteristics

tive of this study was to evaluate the efficacy and safety of Xiaoerchiqiaoqingre granule in the treatment of acute upper respiratory tract infection (AURTI) among children aged 6 months-14 years.

Materials and methods

This study protocol was submitted to and approved by the Institutional Research Ethics Committee of Qilu Hospital, Shandong University, and approval from the parents of each of the participants was acquired. All parents and children gave verbal informed consent. This study also adhered to STROBE guidelines.

The study included 89 acute upper respiratory tract infection children aged 6 months-14 years. All AURTI children were recruited from the pediatric outpatient department. Children who had chronic cardiopulmonary diseases, or suspected of bacteria/mycoplasma infection, or severe symptoms such as accompanied liver, hematology etc abnormality, or suspected of having pneumonia were excluded.

Xiaoerchiqiaoqingre granule (batch number: 20151101) were purchased from Jumpcan Pharmaceutical Group CO., LTD (Taizhou, Jiangsu Province, China). The intervention group was given Xiaoerchiqiaoqingre granule, depended on the age of the child: 2 mg for children younger than 12 months, 3 g for children younger than 2 years, 4 g for children between 2-6 years, and 6 g for children aged 7-14 years. Treatment was given every 8 h for 3 days. The control group was given ribavirin for 3 days. Each child was assessed by one specific and trained pediatrician for clinical signs and symptoms every 12 h for 3 days after enrolment.

All recruited children were assessed for body temperature, dry cough, pharyngitis, running nose, tonsillitis, nasal, and throat congestion. In addition, venous blood samples were drawn at the time of enrolment and then after 72 h for testing the complete blood cell count, ESR, CRP, IL-6, TNF- α , liver function and renal function.

The primary outcome was the proportion of children antipyretic time and fulfilling the criterion of cure at 24 h, 48 h and 72 h after the first dose. The criterion of cure was body temperature ≤37.2°C, cough, nasal discharge, pharyngitis and tonsillitis disappeared or nearly disappeared.

Adverse events, such as vomiting, diarrhea, rash and laboratory tests in both groups were assessed at enrolment and then after 72 h to evaluate the safety.

Statistical analysis

Data are presented as Mean \pm SD, Student's unpaired t-test was performed by SPSS11.0 software to compare the difference. A value of P<0.05 was considered statistically significant.

Results

Subjects

Eighty-nine children (54 boys, 35 girls) with AURTI aged 6 months-14 years participated in this study. The intervention group (n=49) was administered Xiaoerchiqiaoqingre granule and the control group (n=40) was given ribavirin. There were no significant differences in clinical severity, age or laboratory tests between the controls and the intervention group (**Table 1**; <u>Supplementary Data</u>). Demographic and clinical patient characteristics are listed in **Table 1**.

	intervention and control groups (x±3D)		
Laboratory test	Control group	Intervention group	P value
WBC count (×10 ⁹ /L)	8.76±4.66	8.52±5.25	0.79
ESR (mm/h)	32.72±20.54	35.61±17.69	0.83
CRP (mg/L)	18.55±10.35	22.83±11.29	0.67
ALT (IU/L)	30.66±10.38	27.55±7.85	0.76
AST (IU/L)	38.63±13.98	35.23±15.25	0.85
Cr (umol/L)	44.57±10.76	50.64±8.55	0.72
BUN (mmol/L)	5.31±0.56	4.86±1.20	0.56
IL-6 (ng/L)	126.14±9.85	116.87±2.15	0.38
TNF-α (ng/L)	385.33±37.78	415.67±50.36	0.12

Table 2. Comparison of baseline laboratory tests between theintervention and control groups ($\overline{x} \pm SD$)

Note: reference range of laboratory tests: WBC count, 4-10; platelet count, 100-300; ALT, 5-40; AST, 5-40; Cr, 44-133; Bun, 3-7.2.




Figure 1. The proportion of children with fever free over time. Asterisks indicate statistically significant differences in the proportion of fever free between children treated with Xiaoerchiqiaoqingre granule or ribavirin (P<0.01). Intervention group: Xiaoerchiqiaoqingre granule group; Control group: ribavirin.

Baseline laboratory tests between the two groups are presented in (**Table 2**; <u>Supplementary</u> <u>Data</u>).

Efficacy

As shown in **Figure 1**, the proportion of children with fever free at 24 h in the intervention group was 29.8%, it was lightly higher than that of control group (25.5%), the difference between them was not significant; However, the difference was statistically significant at 48 h (52.5% vs 71.4%, P<0.01) and at 72 h (62.5% vs 89.8%, P<0.01) (**Figure 1**). Figure 2 shows the proportion of children fulfilling the criteria of cure over time. No child in either group fulfilled the criteria of cure until 24 h. The intervention group had a higher proportion of children fulfilling the criteria of cure at 48 h as opposed to control group (P<0.05). Significant differences between intervention and control groups were also found in fulfilling the criteria of cure at 72 h (P<0.01) (Figure 2).

Comparison of laboratory test at 72 h between the intervention and control groups are presented in Table 3. ESR. CRP, IL-6 and TNF-α for children of the two groups increased and the two groups were not significantly different at enrolment. However, a significant decrease of the ESR. CRP, IL-6 and TNF- α in the blood at 72 h posttreatment with Xiaoerchigiaogingre granule was recorded compared with those of the control group. At 72 h after treatment, the count of WBC was not significantly different between the control group and intervention group (Table 3; Supplementary Data).

Safety

Meantime we recorded the adverse events of all patients and liver function and renal function at 72 h after treat-

ment. Vomiting and diarrhea were the only clinical adverse events to occur and there was no difference in the proportion of children between the two groups. Liver function and renal function at 72 h after treatment were also within the normal reference ranges (**Table 4**).

Discussion

Respiratory viral infections constitute the most frequent reason for medical consultations in the World. It remains a global burden causing nearly 4 million deaths annually [14]. In developing countries, Respiratory viral infections is

Int J Clin Exp Med 2017;10(9):13653-13658




Figure 2. The proportion of cure children free over time. #indicates statistically significant differences in the cure proportion of children at 48 h following treated with Xiaoerchiqiaoqingre granule or ribavirin (P<0.05). Asterisk indicates statistically significant differences in the cure proportion of children at 72 h following treated with Xiaoerchiqiaoqingre granule or ribavirin (P<0.01). Intervention group: Xiaoerchiqiaoqingre granule group; Control group: ribavirin.

Table 3. Comparison of laboratory tests at 72 h between the intervention and control groups ($\bar{x}\pm SD$)

Laboratory test	Control group	Intervention group	P value
WBC count (×10 ⁹ /L)	7.97±2.12	8.06±2.25	0.81
ESR (mm/h)	25.69±7.89	16.92±7.69	0.035
CRP (mg/L)	15.96±9.65	12.39±9.23	0.023
IL-6 (ng/L)	96.72±15.96	77.43±12.65	0.016
TNF-α (ng/L)	269.97±44.27	198.75±68.54	0.008

Table 4. The adverse events, liver function and renal function of allchildren at 72 h after treatment

	Control group (n=40)	Intervention group (n=49)	P value
Vomiting-n (%)	8 (20%)	11 (22.45%)	0.65
Diarrhea-n (%)	5 (12.5%)	9 (18.37)	0.08
ALT (IU/L) ($\overline{x} \pm SD$)	31.59±12.15	26.69±9.31	0.82
AST (IU/L) ($\overline{x} \pm SD$)	33.63±15.42	35.87±14.92	0.95
Cr (umol/L) (x±SD)	47.23±9.83	45.56±13.68	0.65
BUN (mmol/L) ($\overline{x} \pm SD$)	4.92±1.18	4.35±1.31	0.42

the primary cause of death in children <5 years [15]. Therefore, the prevention and control of these infections remain major clinical goals.

Nowadays, Traditional Chinese medical herbs are widely used for the prevention and treat-

ment of viral infectious diseases in China and many other Asian countries. In this study, the effects and safety of Xiaoerchigiaogingre granule, a Chinese medicine granule, on children with acute upper respiratory tract infection were investigated. Our present study indicated that Xiaoerchigiaogingre granule significantly abated fever, down-regulated ESR, CRP, IL-6 and TNF- α of children with acute upper respiratory tract infection. The clinical signs were alleviated in the Xiaoerchigiaogingre granuletreated group.

From another hand, application of Xiaoerchigiaogingre granule was not shown to result in adverse events in the intervention group. Vomiting and diarrhea were the only clinical adverse events to occur and there was no difference in the proportion of children experiencing these. At the end of the study, the levels of ALT, AST, Cr and BUN were not significantly different. Xiaoerchigiaogingre granule, therefore, can be considered as non-toxic in the treatment of children with acute upper respiratory tract infection.

Respiratory viral infection is manifested by virus-specific reactions with further development of reactive processes. These processes are induced by the replicating virus in the host cells [16] and realized through host mecha-

nisms, including immune reactions, oxidative stress and other free radical processes, enhanced proteolytic activity, sharp elevation of the level of proinflammatory cytokines, and more [17, 18]. In this study, our results demonstrated that the levels of IL-6 and TNF- α were

remarkably increased in children with acute upper respiratory tract infection. This finding agrees with the work of others that has demonstrated that respiratory viral infection can induce cellular production of IL-6 and TNF- α , which were likely to generate respiratory tract inflammation [19]. Therefore, there is a strong correlation between cytokines and respiratory tract inflammation. Traditional Chinese medicine have been previously reported to offer efficient protection against respiratory virus and significantly decrease viral load and inflammation [16]. In this study, treatment with Xiaoerchigiacqingre granule after infection significantly decreased IL-6 and TNF-α levels in comparison to that observed in the control group. These results indicated that Xiaoerchiqiaoqingre granule could be effective in treatment to children with respiratory viral infection, which correlated with the regulation of systemic inflammatory cytokine levels. The regulating effects of Xiaoerchigiaogingre granule on systemic inflammatory cytokine levels were beneficial to alleviate the systemic and respiratory tract inflammatory responses.

Conclusion

In summary, our results demonstrated that Xiaoerchiqiaoqingre granule had a protective activity on acute upper respiratory tract infection, which might be associated with antipyretic, improvement of clinical signs in the course of disease and normalization of ESR and CRP via regulating the cytokine production IL-6 and TNF- α . Moreover, Xiaoerchiqiaoqingre granule did not demonstrate any side effects when applied to children with acute upper respiratory tract infection.

Acknowledgements

This research was funded by National Natural Science Foundation of China (81371337).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xinjie Liu, Department of Pediatrics, Qilu Hospital, Shandong University, 107 Wen Hua Xi Road, Jinan 250012, China. Tel: +86 18560086300; Fax: +86 531 86927544; E-mail: liuxinjie-ert@163.com

References

[1] American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006; 118: 1774-93.

- [2] Fitzgerald DA, Kilham HA. Bronchiolitis: assessment and evidence-based management. Med J Aust 2004; 180: 399-404.
- [3] Ngai P, Bye MR. Bronchiolitis. Pediatr Ann 2002; 31: 90-7.
- [4] Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377: 1264-1275.
- [5] Juve'n T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, Eskola J, Saikku P, Ruuskanen O. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19: 293-298.
- [6] Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, Johnson DW, Klassen TP, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2013; 6: CD004878.
- [7] Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160: 829-34.
- [8] Hartling L, Wiebe N, Russell K, Patel H, Klassen TP. A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med 2003; 157: 957-64.
- [9] Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, Klassen TP, Vandermeer B. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ 2011; 342: d1714.
- [10] Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, Klassen TP, Patel H, Fernandes RM. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2011; 6: CD003123.
- [11] Spurling GK, Doust J, Del Mar CB, Eriksson L. Antibiotics for bronchiolitis in children. Cochrane Database Syst Rev 2011; 6: CD005189.
- [12] Guo R, Pittler MH, Ernst E. Complementary medicine for treating or preventing influenza or influenza-like illness. Am J Med 2007; 120: 923-9, e3.
- [13] Kubo T, Nishimura H. Antipyretic effect of Maoto, a Japanese herbal medicine, for treatment of type a influenza infection in children. Phytomedicine 2007; 14: 96-101.
- [14] Fagbo SF, Garbati MA, Hasan R, AlShahrani D, Al-Shehri M, AlFawaz T, Hakawi A, Wani TA, Skakni L. Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013. J Med Virol 2017; 89: 195-201.
- [15] Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li

M, Mathers C, Black RE; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151-2161.

- [16] Li T and Peng T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. Antiviral Res 2013; 97: 1-9.
- [17] Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999; 44 Suppl: 3-9.
- [18] Zarubaev VV, Garshinina AV, Kalinina NA, Shtro AA, Belyaevskaya SV, Slita AV, Nebolsin VE, Kiselev OI. Activity of ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) against humanrespiratory viruses in in vivo experiments. Pharmaceuticals (Basel) 2011; 4: 1518-1534.
- [19] Lin LL, Shan JJ, Xie T, Xu JY, Shen CS, Di LQ, Chen JB, Wang SC. Application of traditional chinese medical herbs in prevention and treatment of respiratory syncytial virus. Evid Based Complement Alternat Med 2016; 2016: 6082729.

Control group

1.	Male, 11 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.58×10 ⁹ /L, ESR 40 mm/h, CRP 8.25 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 60 umol/L, BUN 3.8 mmol/L, IL-6 115 ng/L, TNF-α 347 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever, Tonsillitis.
	At 48 h after treatment: Cough relieved, Nasal discharge relieved, Fever free, Tonsillitis.
	At 72 h after treatment: symptom disappeared
	No vomiting, no diarrhea. WBC count 7.98×10 ⁹ /L, ESR 35 mm/h, CRP 6.36 mg/L, ALT 31 IU/L, AST
	28 IU/L, Cr 44 umol/L, BUN 5.2 mmol/L. IL-6 81 ng/L, TNF-α 225 ng/L.
2.	Female, 10 years, 30 Kg, 148 cm. Cough, Nasal discharge, Fever free,
	WBC count 9.58×10 ⁹ /L, ESR 23 mm/h, CRP 6.25 mg/L, ALT 20 IU/L, AST 18 IU/L, Cr 68 umol/L, BUN
	6.3 mmol/L, IL-6 115 ng/L, TNF-α 345 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever free.
	At 48 h after treatment: symptom disappeared
	At 72 h after treatment:
	No vomiting, no diarrhea. WBC count 7.08×10 ⁹ /L, ESR 7 mm/h, CRP 4.36 mg/L, ALT 33 IU/L, AST 30
	IU/L, Cr 65 umol/L, BUN 4.3 mmol/L. IL-6 83 ng/L, TNF-α 230 ng/L.
З.	Male, 1 year and 1 month, 12 Kg, 77 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	WBC count 15.86×10 ⁹ /L, ESR 53 mm/h, CRP 18.26 mg/L, ALT 30 IU/L, AST 25 IU/L, Cr 53 umol/L,
	BUN 7. 18 mmol/L, IL-6 130 ng/L, TNF-α 402 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	No vomiting, no diarrhea. WBC count 12.75×10 ⁹ /L, ESR 35 mm/h, CRP 6.72 mg/L, ALT31 IU/L,
	AST22 IU/L, Cr40 umol/L, BUN 3.6 mmol/L. IL-6 122 ng/L, TNF-α 302 ng/L.
4.	Male, 1 year and six months, 13 Kg, 78 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	WBC count 11.77×10 ⁹ /L, ESR 37 mm/h, CRP 12.65 mg/L, ALT 20 IU/L, AST 32 IU/L, Cr 52 umol/L,
	BUN 7.08 mmol/L, IL-6 125 ng/L, TNF-α 415 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 72 h after treatment still cough, other symptoms disappeared
	No vomiting, no diarrhea. WBC count 7.98×10 ⁹ /L, ESR 35 mm/h, CRP 6.36 mg/L, ALT 31 IU/L, AST
_	28 IU/L, Cr 44 umol/L, BUN 5.2 mmol/L. IL-6 81 ng/L, TNF- α 225 ng/L.
э.	Male, 10 months, 9 Kg, 76 cm. Cough, Fever free, Pharyngitis, Tonsillitis.
	WBC count 8.69×10 ⁹ /L, ESR 23 mm/h, CRP 7.32 mg/L, ALT 35 IU/L, AST 28 IU/L, Cr 62 umol/L, BUN
	4.8 mmol/L, IL-6 120 ng/L, TNF- α 350 (ng/L)
	At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
	At 48 h after treatment: Cough, fever free
	At 72 h after treatment: symptoms disappeared No vomiting, no diarrhea. WBC count 5.68×10 ⁹ /L, ESR 18 mm/h, CRP 3.58 mg/L, ALT 25 IU/L, AST
	30 IU/L , Cr 60 umol/L, BUN 5.2 mmol/L. IL-6 99 ng/L, TNF- α 272 ng/L.
6	Female, 3 years, 16 Kg, 95 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
0.	WBC count 13.76×10^9 /L, ESR 55 mm/h, CRP 45.25 mg/L, ALT 26 IU/L, AST 28 IU/L, Cr 63 umol/L,
	BUN 4.8 mmol/L, IL-6 130 ng/L, TNF- α 370 (ng/L)
	At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 72 h after treatment: fever free, other symptoms remained
	No vomiting, no diarrhea. WBC count 10.55×10 ⁹ /L, ESR 40 mm/h, CRP 10.36 mg/L, ALT 31 IU/L,
	AST 23 IU/L, Cr 50 umol/L, BUN 3.2 mmol/L. IL-6 102 ng/L, TNF- α 305 ng/L.
7	Female, 3 years, 15 Kg, 95 cm. Cough, Nasal discharge, fever free.
	WBC count 9.58×10 ⁹ /L, ESR 15 mm/h, CRP 5.25 mg/L, ALT 20 IU/L, AST 18 IU/L, Cr 56 umol/L, BUN
	2.8 mmol/L, IL-6 113 ng/L, TNF- α 305 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge fever free.

At 48 h after treatment: Fever free, Cough, Nasal discharge.

At 72 h after treatment: symptoms disappeared

No vomiting, no diarrhea. WBC count 6.98×10⁹/L, ESR 15 mm/h, CRP 3.36 mg/L, ALT 15 IU/L, AST 20 IU/L, Cr 55 umol/L, BUN 5.2 mmol/L. IL-6 110 ng/L, TNF-α 287 ng/L.

Male, 8 months, 8 Kg, 76 cm. Cough, Nasal discharge, Fever free. WBC count 5.69×10⁹/L, ESR 21 mm/h, CRP 8.58 mg/L, ALT 20 IU/L, AST 18 IU/L, Cr 59 umol/L, BUN 3.78 mmol/L, IL-6 118 ng/L, TNF-α 342 (ng/L) At 24 h after treatment: Cough, Nasal discharge, fever free. At 48 h after treatment: Cough, Nasal discharge, fever free. At 72 h after treatment: Cough, Nasal discharge, fever free. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 35 mm/h, CRP 6.36 mg/L, ALT 20 IU/L, AST 25 IU/L, Cr 52 umol/L, BUN 6.2 mmol/L. IL-6 120 ng/L, TNF-α 360 ng/L. 9. Female, 11 years, 32 Kg, 150 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 14.85×10⁹/L, ESR 58 mm/h, CRP 35.54 mg/L, ALT 44 IU/L, AST 56 IU/L, Cr 58 umol/L, BUN 4.78 mmol/L, IL-6 130 ng/L, TNF-α 425 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.

- At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
- At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
- no vomiting, no diarrhea. WBC count 10.28×10⁹/L, ESR 45 mm/h, CRP 17.55 mg/L, ALT 35 IU/L, AST 25 IU/L, Cr 54 umol/L, BUN 5.2 mmol/L. IL-6 116 ng/L, TNF-α 358 ng/L.
- 10. Female, 1 year and 8 months, 13 Kg, 80 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 8.92×10⁹/L, ESR 32 mm/h, CRP 7.25 mg/L, ALT 27 IU/L, AST 36 IU/L, Cr 51 umol/L, BUN 3.5 mmol/L, IL-6 105 ng/L, TNF-α 307 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Tonsillitis. At 72 h after treatment : fever disappeared, other symptoms remained. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 35 mm/h, CRP 6.35 mg/L, ALT 30 IU/L, AST

23 IU/L, Cr 48 umol/L, BUN 5.5 mmol/L. IL-6 95 ng/L, TNF-α 262 ng/L.

- 11. Male, 1 year and 3 months, 11 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.58×10⁹/L, ESR 23 mm/h, CRP 9.32 mg/L, ALT 27 IU/L, AST 32 IU/L, Cr 59 umol/L, BUN 3.7 mmol/L, IL-6 1110 ng/L, TNF-α 357 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
 - At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
 - At 72 h after treatment : symptoms remained

No vomiting, no diarrhea. WBC count 10.98×10⁹/L, ESR 25 mm/h, CRP 9.97 mg/L, ALT 21 IU/L, AST 24 IU/L, Cr 54 umol/L, BUN 3.54 mmol/L. IL-6 130 ng/L, TNF-α 305 ng/L.

12. Male, 1 year and 2 months, 12 Kg, 75 cm. Fever, Pharyngitis, Tonsillitis. WBC count 9.58×10⁹/L, ESR 40 mm/h, CRP 8.25 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 75 umol/L, BUN 3.8 mmol/L, IL-6 115 ng/L, TNF-α 347 (ng/L) At 24 h after treatment: Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: fever free, Tonsillitis. At 72 h after treatment: fever free, Tonsillitis.

No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 20 mm/h, CRP 6.36 mg/L, ALT 37 IU/L, AST 32 IU/L, Cr 54 umol/L, BUN 4.2 mmol/L. IL-6 96 ng/L, TNF-α 255 ng/L.

13. Male, 1 year and 3 months, 12 Kg, 77 cm. Nasal discharge, Fever. WBC count 8.58×10⁹/L, ESR 20 mm/h, CRP 6.36 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr 56 umol/L, BUN 4.8 mmol/L, IL-6 120 ng/L, TNF-α 358 (ng/L) At 24 h after treatment: Nasal discharge, Fever. At 48 h after treatment: Fever free, other symptoms remained. At 72 h after treatment all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 13 mm/h, CRP 5.36 mg/L, ALT 35 IU/L, AST 25 IU/L, Cr 50 umol/L, BUN 3.2 mmol/L. IL-6 90 ng/L, TNF-α 215 ng/L.

14. Male, 11 months, 10 Kg, 76 cm. Nasal discharge, Fever free.

Protective effects of traditional Chinese medicine on children with respiratory

WBC count 9.58×10⁹/L, ESR 10 mm/h, CRP 4.25 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 82 umol/L, BUN 3.8 mmol/L, IL-6 82 ng/L, TNF-α 247 (ng/L) At 24 h after treatment: Fever free, Nasal discharge. At 48 h after treatment: all symptoms disappear. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.85×10⁹/L, ESR 15 mm/h, CRP 3.36 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr50 umol/L, BUN 4.2 mmol/L. IL-6 91 ng/L, TNF-α 215 ng/L. 15. Male, 1 year and 7 months, 13 Kg, 78 cm. Cough, Fever free, Pharyngitis, Tonsillitis. WBC count 11.36×10⁹/L, ESR 23 mm/h, CRP 7.55 mg/L, ALT 26 IU/L, AST 15 IU/L, Cr 63 umol/L, BUN 5.8 mmol/L, IL-6 1225 ng/L, TNF-α 367 (ng/L) At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 9.98×10⁹/L, ESR 17 mm/h, CRP 5.36 mg/L, ALT 30 IU/L, AST 25 IU/L, Cr 48 umol/L, BUN 3.5 mmol/L. IL-6 98 ng/L, TNF-α 235 ng/L. 16. Male, 1 year and 9 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis. WBC count 9.75×10⁹/L, ESR 19 mm/h, CRP 7.45 mg/L, ALT 23 IU/L, AST 16 IU/L, Cr 53 umol/L, BUN 4.1 mmol/L, IL-6 118 ng/L, TNF-α 345 (ng/L) At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 7.78×10⁹/L, ESR 15 mm/h, CRP 7.35 mg/L, ALT 26 IU/L, AST 21 IU/L, Cr 50 umol/L, BUN 6.2 mmol/L. IL-6 95 ng/L, TNF-α 218 ng/L. 17. Female, 1 year and 4 months, 13 Kg, 76 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 9.96×10⁹/L, ESR 27 mm/h, CRP 9.93 mg/L, ALT 26 IU/L, AST 33 IU/L, Cr 56 umol/L, BUN 6.7 mmol/L, IL-6 135 ng/L, TNF-α 358 (ng/L) At 24 h after treatment: Cough, fever. At 48 h after treatment: Cough remained, Fever free. At 72 h after treatment :All symptoms disappeared. No vomiting, no diarrhea. WBC count 6.98×10°/L, ESR 15 mm/h, CRP 6.36 mg/L, ALT 34 IU/L, AST 33 IU/L, Cr 58 umol/L, BUN 4.6 mmol/L. IL-6 88 ng/L, TNF-α 230 ng/L. 18. Female, 1 year and 9 months, 13 Kg, 76 cm. Nasal discharge, Pharyngitis, Tonsillitis, Fever free. WBC count 9.58×10⁹/L, ESR 20 mm/h, CRP 7.47 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 58 umol/L, BUN 3.8 mmol/L, IL-6 115 ng/L, TNF-α 347 (ng/L) At 24 h after treatment: Nasal discharge, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.59×10⁹/L, ESR 12 mm/h, CRP 6.57 mg/L, ALT 33 IU/L, AST 26 IU/L, Cr 49 umol/L, BUN 4.9 mmol/L. IL-6 85 ng/L, TNF-α 235 ng/L. 19. Female, 7 months, 8.5 Kg, 73 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.93×10⁹/L, ESR 37 mm/h, CRP 10.54 mg/L, ALT 24 IU/L, AST 25 IU/L, Cr 58 umol/L, BUN 6.1 mmol/L, IL-6 135 ng/L, TNF-α 397 (ng/L) At 24 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Nasal discharge, Fever, Tonsillitis. No vomiting, no diarrhea. WBC count 11.13×10⁹/L, ESR 35 mm/h, CRP 25.36 mg/L, ALT 37 IU/L, AST 38 IU/L, Cr66 umol/L, BUN 5.2 mmol/L. IL-6 136 ng/L, TNF-α 425 ng/L. 20. Male, 8 months, 9.5 Kg, 74 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.83×10⁹/L, ESR 23 mm/h, CRP 8.76 mg/L, ALT 22 IU/L, AST 35 IU/L, Cr 65 umol/L, BUN 4.4 mmol/L, IL-6 120 ng/L, TNF-α 360 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.

At 72 h after treatment : All symptoms disappeared.

No vomiting, no diarrhea. WBC count 7.86×10⁹/L, ESR 20 mm/h, CRP 6.89 mg/L, ALT 30 IU/L, AST 23 IU/L, Cr 61 umol/L, BUN 6.7 mmol/L. IL-6 100 ng/L, TNF- α 232 ng/L.

21. Male, 2 years and 1 month, 14 Kg, 86 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 8.95×10⁹/L, ESR 22 mm/h, CRP 9.69 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr 49 umol/L, BUN 3.3 mmol/L, IL-6 128 ng/L, TNF-α 388 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis. At 48 h after treatment: Cough, Fever, Pharyngitis. At 72 h after treatment : All symptoms disappeared. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 3 5mm/h, CRP 6.36 mg/L, ALT 31 IU/L, AST 28 IU/L, Cr44 umol/L, BUN 5.2 mmol/L. IL-6 81 ng/L, TNF-α 225 ng/L. 22. Male, 4 years, 16 Kg, 100 cm. Cough, Nasal discharge, Pharyngitis, Fever, Tonsillitis. WBC count 9.77×10⁹/L, ESR 20 mm/h, CRP 8.9 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr 63 umol/L, BUN 3.8 mmol/L, IL-6 125 ng/L, TNF-α 357 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Cough, Nasal discharge, Fever free. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 6.58×10°/L, ESR 14 mm/h, CRP 5.36 mg/L, ALT 24 IU/L, AST 24 IU/L, Cr 68 umol/L, BUN 4.2 mmol/L. IL-690 ng/L, TNF-α 223 ng/L. 23. Female, 2 years and 2 months, 14 Kg, 87 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.35×10⁹/L, ESR 35 mm/h, CRP 30.28 mg/L, ALT 23 IU/L, AST 33 IU/L, Cr 53 umol/L, BUN 4.2 mmol/L, IL-6 136 ng/L, TNF-α 425 (ng/L) At 24 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment : Nasal discharge, Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 10.98×10⁹/L, ESR 35 mm/h, CRP 27.36 mg/L, ALT 36 IU/L, AST 28 IU/L, Cr 55 umol/L, BUN 5.2 mmol/L. IL-6 133 ng/L, TNF-α 404 ng/L. 24. Female, 11 months, 10 Kg, 76 cm. Nasal discharge, Fever free, Pharyngitis, Tonsillitis. WBC count 9.58×10⁹/L, ESR 40 mm/h, CRP 8.25 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 84 umol/L, BUN 3.8 mmol/L, IL-6 115 ng/L, TNF-α 347 (ng/L) At 24 h after treatment: Nasal discharge, Fever free. At 48 h after treatment: all symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 7 mm/h, CRP 6.35 mg/L, ALT 25 IU/L, AST17 IU/L, Cr 44 umol/L, BUN 3.2 mmol/L. IL-6 90 ng/L, TNF-α 220 ng/L. 25. Male, 10 months, 9.5 Kg, 75 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 11.76×10⁹/L, ESR 50 mm/h, CRP 30.25mg/L, ALT 42 IU/L, AST 53 IU/L, Cr 63 umol/L, BUN 3.5 mmol/L, IL-6 136 ng/L, TNF-α 397 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment : Cough, Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 9.98×10⁹/L, ESR 35 mm/h, CRP 29.36 mg/L, ALT 32 IU/L, AST 20 IU/L, Cr 47 umol/L, BUN 3.2 mmol/L. IL-6 134 ng/L, TNF-α 410 ng/L. 26. Female, 3 years and 2months, 16 Kg, 95 cm. Cough, Pharyngitis, Fever, Tonsillitis. WBC count 9.35×10⁹/L, ESR 18 mm/h, CRP 7.86 mg/L, ALT 26 IU/L, AST 38 IU/L, Cr 56 umol/L, BUN 3.3 mmol/L, IL-6 121 ng/L, TNF-α 353 (ng/L) At 24 h after treatment: Cough, Fever. At 48 h after treatment: Cough, Fever free. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.31×10⁹/L, ESR 10 mm/h, CRP 6.36 mg/L, ALT 30 IU/L, AST 28 IU/L, Cr 47 umol/L, BUN 6.2 mmol/L. IL-6 98 ng/L, TNF-α 245 ng/L. 27. Male, 7 years, 25 Kg, 122 cm. Cough, Nasal discharge, Fever free, Tonsillitis. WBC count 9.51×10°/L, ESR 20 mm/h, CRP 4.68 mg/L, ALT 20 IU/L, AST 22 IU/L, Cr 62 umol/L, BUN 3.1 mmol/L, IL-6 117 ng/L, TNF-α 395 (ng/L)

At 24 h after treatment: Cough, Nasal discharge, Fever free.

At 48 h after treatment: all symptoms disappeared.

At 72 h after treatment

No vomiting, no diarrhea. WBC count 5.98×10°/L, ESR 13 mm/h, CRP 3.36 mg/L, ALT 32 IU/L, AST 28 IU/L, Cr 50 umol/L, BUN 5.1 mmol/L. IL-6 85 ng/L, TNF-α 222 ng/L.

- 28. Male, 1 year and 7 months, 12 Kg, 80 cm. Cough, Fever, Tonsillitis.
- WBC count 5.49×10⁹/L, ESR 23 mm/h, CRP 4.25 mg/L, ALT 20 IU/L, AST 18 IU/L, Cr 53 umol/L, BUN 3.2 mmol/L, IL-6 1118 ng/L, TNF-α 369 (ng/L)
 - At 24 h after treatment: Cough, Fever.
 - At 48 h after treatment: Cough, Fever free.
 - At 72 h after treatment : all symptoms disappeared.

No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 11 mm/h, CRP 3.36 mg/L, ALT 31 IU/L, AST 20 IU/L, Cr54 umol/L, BUN 3.2 mmol/L. IL-6 117 ng/L, TNF-α 285 ng/L.

29. Female, 1 year and 5 months, 11.5 Kg, 78 cm. Nasal discharge, Pharyngitis, Fever, Tonsillitis . WBC count 9.58×10⁹/L, ESR 24 mm/h, CRP 3.75 mg/L, ALT 27 IU/L, AST 35 IU/L, Cr 52 umol/L, BUN 3.2 mmol/L, IL-6 123 ng/L, TNF-α 397 (ng/L) At 24 h after treatment: Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Nasal discharge, Fever free. At 72 h after treatment: all symptoms disappeared.

At 72 h after treatment

No vomiting, no diarrhea. WBC count 6.66×10⁹/L, ESR 15 mm/h, CRP 4.36 mg/L, ALT 33 IU/L, AST 25 IU/L, Cr 57 umol/L, BUN 4.5 mmol/L. IL-697 ng/L, TNF-α 275 ng/L.

- 30. Male, 9 years, 28 Kg, 140 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.34×10⁹/L, ESR 20 mm/h, CRP 4.76 mg/L, ALT 20 IU/L, AST 25 IU/L, Cr 56 umol/L, BUN 3.7 mmol/L, IL-6 130 ng/L, TNF-α 407 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever.
 - At 48 h after treatment: Cough, Nasal discharge, Fever free.
 - At 72 h after treatment: all symptoms disappeared.

No vomiting, no diarrhea. WBC count 6.57×10⁹/L, ESR 8 mm/h, CRP 6.76 mg/L, ALT 35 IU/L, AST 30 IU/L, Cr 63 umol/L, BUN 4.3 mmol/L. IL-6 98 ng/L, TNF-α 257 ng/L.

31. Male, 9 years, 32 Kg, 145 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.88×10⁹/L, ESR 17 mm/h, CRP 5.25 mg/L, ALT 34 IU/L, AST 35 IU/L, Cr 51 umol/L, BUN 3.5 mmol/L, IL-6 135 ng/L, TNF-α 396 (ng/L) At 24 h after treatment: Nasal discharge, Pharyngitis, Tonsillitis, Fever. At 48 h after treatment: Nasal discharge, Fever free. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 5.37×10°/L, ESR 10 mm/h, CRP 4.15 mg/L, ALT 22 IU/L, AST

28 IU/L, Cr 55 umol/L, BUN 3.8 mmol/L. IL-6 85 ng/L, TNF-α 295 ng/L. 32. Female, 11 years, 35 Kg, 150 cm. Cough, Nasal discharge, Pharyngitis, Fever free, Tonsillitis. WBC count 5.58×10⁹/L, ESR 14 mm/h, CRP 4.33 mg/L, ALT 21 IU/L, AST 34 IU/L, Cr 62 umol/L, BUN 3.5 mmol/L, IL-6 145 ng/L, TNF-α 387 (ng/L) At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.57×10°/L, ESR 7 mm/h, CRP 3.65 mg/L, ALT 30 IU/L, AST

28 IU/L, Cr 54 umol/L, BUN 3.2 mmol/L. IL-6 90 ng/L, TNF-α 285 ng/L.

33. Female, 6 years, 15 Kg, 103 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 12.58×10⁹/L, ESR 40 mm/h, CRP8.25 mg/L, ALT 23 IU/L, AST 35 IU/L, Cr 52 umol/L, BUN 3.6 mmol/L, IL-6 177 ng/L, TNF-α 393 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 11.23×10⁹/L, ESR 35 mm/h, CRP 7.34 mg/L, ALT 30 IU/L, AST 28 IU/L, Cr 44 umol/L, BUN 5.2 mmol/L. IL-6 81 ng/L, TNF-α 225 ng/L. 34. Male, 8 year, 27 Kg, 112 cm. Fever, Pharyngitis, Tonsillitis.

Protective effects of traditional Chinese medicine on children with respiratory

WBC count 15.96×10⁹/L, ESR 48 mm/h, CRP 28.25 mg/L, ALT 23 IU/L, AST 32 IU/L, Cr 52 umol/L, BUN 3.9 mmol/L, IL-6 135 ng/L, TNF-α 420 (ng/L) At 24 h after treatment: Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 14.67×10°/L, ESR 40 mm/h, CRP 16.35 mg/L, ALT 30 IU/L, AST 23 IU/L, Cr 49 umol/L, BUN 3.1 mmol/L. IL-6 138 ng/L, TNF-α 315 ng/L. 35. Male, 11 months, 10.5 Kg, 78 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 13.45×10⁹/L, ESR 36 mm/h, CRP 19.36 mg/L, ALT 29 IU/L, AST 23 IU/L, Cr 64 umol/L, BUN 3.5 mmol/L, IL-6 133 ng/L, TNF-α 417 (ng/L) At 24 h after treatment: Cough, Fever, Tonsillitis. At 48 h after treatment: Cough, Fever, Tonsillitis. At 72 h after treatment: Cough, Fever, Tonsillitis. No vomiting, no diarrhea. WBC count 14.98×10⁹/L, ESR 35 mm/h, CRP 16.52 mg/L, ALT 35 IU/L, AST 26 IU/L, Cr 45 umol/L, BUN 5.3 mmol/L. IL-6 112 ng/L, TNF-α 315 ng/L. 36. Female, 6 years, 123 Kg, 116 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 7.24×10⁹/L, ESR 20 mm/h, CRP 7.25 mg/L, ALT 31 IU/L, AST 16 IU/L, Cr 50 umol/L, BUN 4.0 mmol/L, IL-6 123 ng/L, TNF-α 386 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Cough, Nasal discharge, Fever free. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 15 mm/h, CRP 6.37 mg/L, ALT 37 IU/L, AST 22 IU/L, Cr 45 umol/L, BUN 4.2 mmol/L. IL-6 89 ng/L, TNF-α 265 ng/L. 37. Male, 11 months, 10 Kg, 76 cm. Fever, Pharyngitis, Tonsillitis. WBC count 9.58×10º/L, ESR 36 mm/h, CRP 18.76 mg/L, ALT 30 IU/L, AST 40 IU/L, Cr 44 umol/L, BUN 3.2 mmol/L, IL-6 135 ng/L, TNF-α 425 (ng/L) At 24 h after treatment: Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 35 mm/h, CRP 16.26 mg/L, ALT 31 IU/L, AST 32 IU/L, Cr 49 umol/L, BUN 5.5 mmol/L. IL-6 130 ng/L, TNF-α 416 ng/L. 38. Male, 1 year and 2 months, 11 Kg, 79 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 3.62×10⁹/L, ESR 35 mm/h, CRP 23.49 mg/L, ALT 38 IU/L, AST 32 IU/L, Cr 67 umol/L, BUN 7.2 mmol/L, IL-6 131 ng/L, TNF-α 408 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 33 mm/h, CRP 19.36 mg/L, ALT 31 IU/L, AST 23 IU/L, Cr 58 umol/L, BUN 3.9 mmol/L. IL-6 129 ng/L, TNF-α 395 ng/L. 39. Male, 1 year and 5 months, 13 Kg, 77 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 3.58×10⁹/L, ESR 40 mm/h, CRP 18.95 mg/L, ALT 23 IU/L, AST 35 IU/L, Cr 48 umol/L, BUN 3.8 mmol/L, IL-6 125 ng/L, TNF-α 387 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Cough, Fever, Tonsillitis. No vomiting, no diarrhea. WBC count 10.36×109/L, ESR 35 mm/h, CRP 16.35 mg/L, ALT 21 IU/L, AST 27 IU/L, Cr 48 umol/L, BUN 5.5 mmol/L. IL-6 132 ng/L, TNF-α 385 ng/L. 40. Male, 1 year and 10 months, 13.5 Kg, 80 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 4. 85×10⁹/L, ESR 53 mm/h, CRP 30 mg/L, ALT 42 IU/L, AST 53 IU/L, Cr 55 umol/L, BUN 5.8 mmol/L, IL-6 135 ng/L, TNF-α 427 (ng/L) At 24 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis.

No vomiting, no diarrhea. WBC count 9.89×10⁹/L, ESR 33 mm/h, CRP 25 mg/L, ALT 31 IU/L, AST 29 IU/L, Cr 54 umol/L, BUN 5.2 mmol/L. IL-6 135 ng/L, TNF- α 367 ng/L.

Trial group

1.	Male, 11 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.96×10 ⁹ /L, ESR 40 mm/h, CRP 10.47 mg/L, ALT 23 IU/L, AST 30 IU/L, Cr 49 umol/L, BUN 3.8 mmol/L, IL-6 115 ng/L, TNF-α 347 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever, Tonsillitis. At 48 h after treatment: Cough relieved, Nasal discharge relieved, Fever free, Tonsillitis.
	At 72 h after treatment: symptom disappeared No vomiting, no diarrhea. WBC count 7.98×10 ⁹ /L, ESR 36 mm/h, CRP 6.33 mg/L, ALT 33 IU/L, AST 28 IU/L, Cr 48 umol/L, BUN 5.2 mmol/L. IL-6 84 ng/L, TNF-α 228 ng/L.
2.	Female, 10 years, 30 Kg, 148 cm. Cough, Nasal discharge, Fever free, WBC count 10.58×10 ⁹ /L, ESR 28 mm/h, CRP 8.97 mg/L, ALT 29 IU/L, AST 36 IU/L, Cr 44 umol/L,
	BUN 5.3 mmol/L, IL-6 115 ng/L, TNF- α 365 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever free.
	At 48 h after treatment: symptom disappeared
	At 72 h after treatment: No vomiting, no diarrhea. WBC count 7.38×10 ⁹ /L, ESR 13 mm/h, CRP 6.36 mg/L, ALT 31 IU/L, AST
3.	30 IU/L, Cr 72 umol/L, BUN 4.3 mmol/L. IL-6 87 ng/L, TNF-α 235 ng/L. Male, 1 year and 1 month, 12 Kg, 77 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	WBC count 15.83×10 ⁹ /L, ESR 53 mm/h, CRP 18.97 mg/L, ALT 30 IU/L, AST 35 IU/L, Cr 55 umol/L, BUN 3.8 mmol/L, IL-6 133 ng/L, TNF-α 388 (ng/L)
	At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	No vomiting, no diarrhea. WBC count 12.45×10 ⁹ /L, ESR 35 mm/h, CRP 6.74 mg/L, ALT 37 IU/L, AST22 IU/L, Cr 49 umol/L, BUN 4.6 mmol/L. IL-6 142 ng/L, TNF-α 322 ng/L.
4.	. Male, 1 year and six month, 13 Kg, 78 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 11.97×10 ⁹ /L, ESR 37 mm/h, CRP 12.65 mg/L, ALT 29 IU/L, AST 36 IU/L, Cr 58 umol/L,
	BUN 4.58 mmol/L, IL-6 120 ng/L, TNF-α 405 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.
	At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment symptoms disappeared
	No vomiting, no diarrhea. WBC count 7.95×10 ⁹ /L, ESR 35 mm/h, CRP 6.34 mg/L, ALT 32 IU/L, AST
5.	28 IU/L, Cr 44 umol/L, BUN 5.2 mmol/L. IL-6 87 ng/L, TNF-α 255 ng/L. . Male, 1 year and 7 months, 13 Kg, 78 cm. Cough, Fever free, Pharyngitis, Tonsillitis.
	WBC count 11.36×10 ⁹ /L, ESR 23 mm/h, CRP 7.35 mg/L, ALT 26 IU/L, AST 13 IU/L, Cr 63 umol/L, BUN 5.4 mmol/L, IL-6 145 ng/L, TNF-α 366 (ng/L)
	At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared.
	At 72 h after treatment
	No vomiting, no diarrhea. WBC count 9.94×10^9 /L, ESR 17 mm/h, CRP 5.35 mg/L, ALT 34 IU/L, AST 25 IU/L, Cr 48 umol/L, BUN 3.7 mmol/L. IL-6 93 ng/L, TNF- α 238 ng/L.
6.	. Male, 10 months, 9 Kg, 76 cm. Cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis. WBC count 8.61×10 ⁹ /L, ESR 23 mm/h, CRP 7.35 mg/L, ALT 35 IU/L, AST 28 IU/L, Cr 62 umol/L, BUN
	4.8 mmol/L, IL-6 125 ng/L, TNF-α 357 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
	At 48 h after treatment: Cough, fever free At 72 h after treatment: symptoms disappeared
	No vomiting, no diarrhea. WBC count 5.62×10 ⁹ /L, ESR 18 mm/h, CRP 3.78 mg/L, ALT27 IU/L, AST
7.	30 IU/L, Cr 62 umol/L, BUN 5.4 mmol/L. IL-6 99 ng/L, TNF-α 278 ng/L. Female, 3 years, 16 Kg, 95 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.

WBC count 13.36×10⁹/L, ESR 55 mm/h, CRP 35.25 mg/L, ALT 23 IU/L, AST 38 IU/L, Cr 63 umol/L, BUN 5.8 mmol/L, IL-6 134 ng/L, TNF-α 377 (ng/L) At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: fever free, all symptoms disappeared No vomiting, no diarrhea. WBC count 10.55×10⁹/L, ESR 35 mm/h, CRP 10.35 mg/L, ALT 36 IU/L, AST 23 IU/L, Cr 50 umol/L, BUN 3.8 mmol/L. IL-6 122 ng/L, TNF-α 335 ng/L. 8. Female, 3 years, 15 Kg, 95 cm. Cough, Nasal discharge, fever free. WBC count 9.96×10°/L, ESR 19 mm/h, CRP 5.25 mg/L, ALT 27 IU/L, AST 18 IU/L, Cr 58 umol/L, BUN 3.8 mmol/L, IL-6 113 ng/L, TNF-α 325 (ng/L) At 24 h after treatment: Cough, Nasal discharge fever free. At 48 h after treatment: Fever free, Cough, Nasal discharge. At 72 h after treatment: symptoms disappeared No vomiting, no diarrhea. WBC count 6.96×10⁹/L, ESR 12 mm/h, CRP 4.35 mg/L, ALT 15 IU/L, AST 25 IU/L, Cr 55 umol/L, BUN 5.6 mmol/L. IL-6 117 ng/L, TNF-α 288 ng/L. 9. Male, 8 months, 8 Kg, 76 cm. Cough, Nasal discharge, Fever free. WBC count 5.71×10°/L, ESR 21 mm/h, CRP 8.58 mg/L, ALT 26 IU/L, AST 38 IU/L, Cr 53 umol/L, BUN 3.77 mmol/L, IL-6 118 ng/L, TNF-α 347 (ng/L) At 24 h after treatment: Cough, Nasal discharge, fever free. At 48 h after treatment: Cough, Nasal discharge, fever free. At 72 h after treatment: Cough, Nasal discharge, fever free. no vomiting, no diarrhea. WBC count 7.46×10⁹/L, ESR 25 mm/h, CRP 7.37 mg/L, ALT 26 IU/L, AST 25 IU/L, Cr 58 umol/L, BUN 6.1 mmol/L. IL-6 102 ng/L, TNF-α 312 ng/L. 10. Female, 11 years, 32 Kg, 150 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 14.85×10°/L, ESR 58 mm/h, CRP 35.54 mg/L, ALT 48 IU/L, AST 56 IU/L, Cr 58 umol/L, BUN 2.78 mmol/L, IL-6 130 ng/L, TNF-α 425 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. no vomiting, no diarrhea. WBC count 10.28×10⁹/L, ESR 48 mm/h, CRP 17.55 mg/L, ALT 38 IU/L, AST 25 IU/L, Cr 54 umol/L, BUN 5.5 mmol/L. IL-6 146 ng/L, TNF-α 398 ng/L. 11. Female, 1 year and 8 month, 13 Kg, 80 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 8.68×10⁹/L, ESR 35 mm/h, CRP 7.28 mg/L, ALT 26 IU/L, AST 36 IU/L, Cr 59 umol/L, BUN 3.5 mmol/L, IL-6 105 ng/L, TNF-α 309 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Tonsillitis. At 72 h after treatment: fever disappeared, other symptoms remained. No vomiting, no diarrhea. WBC count 7.22×10⁹/L, ESR 32 mm/h, CRP 6.35 mg/L, ALT 30 IU/L, AST 23 IU/L, Cr 88 umol/L, BUN 5.5 mmol/L. IL-6 98 ng/L, TNF-α 282 ng/L. 12. Male, 11 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.89×10⁹/L, ESR 40 mm/h, CRP 8.25 mg/L, ALT 27 IU/L, AST 30 IU/L, Cr 75 umol/L, BUN 3.9 mmol/L, IL-6 120 ng/L, TNF-α 350 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Tonsillitis. At 48 h after treatment: symptom disappeared. At 72 h after treatment: symptom disappeared no vomiting, no diarrhea. WBC count 7.95×10⁹/L, ESR 25 mm/h, CRP 6.32 mg/L, ALT 33 IU/L, AST 28 IU/L, Cr 49 umol/L, BUN 5.5 mmol/L. IL-6 85 ng/L, TNF-α 230 ng/L. 13. Male, 1 year and 3 months, 11 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.55×10⁹/L, ESR 23 mm/h, CRP 9.35 mg/L, ALT 25 IU/L, AST 32 IU/L, Cr 59 umol/L, BUN 3.7 mmol/L, IL-6 130 ng/L, TNF-α 353 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis.

At 72 h after treatment: all symptoms disappeared

No vomiting, no diarrhea. WBC count 10.98×10⁹/L, ESR 25 mm/h, CRP 9.95 mg/L, ALT 27 IU/L, AST 24 IU/L, Cr 53 umol/L, BUN 3.55 mmol/L. IL-6 137 ng/L, TNF-α 373 ng/L. 14. Male, 1 year and 2 months, 12 Kg, 75 cm. Fever, Pharyngitis, Tonsillitis. WBC count 9.58×10⁹/L, ESR 40 mm/h, CRP 8.25 mg/L, ALT 26 IU/L, AST 30 IU/L, Cr 47 umol/L, BUN 3.9 mmol/L, IL-6 116 ng/L, TNF-α 354 (ng/L) At 24 h after treatment: Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: fever free, Tonsillitis. At 72 h after treatment : fever free, all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.93×10⁹/L, ESR 20 mm/h, CRP 6.35 mg/L, ALT 34 IU/L, AST 32 IU/L, Cr 56 umol/L, BUN 4.2 mmol/L. IL-6 98 ng/L, TNF-α 256 ng/L. 15. Male, 1 year and 3 months, 12 Kg, 77 cm. Nasal discharge, Fever, Tonsillitis. WBC count 8.55×10⁹/L, ESR 20 mm/h, CRP 6.35 mg/L, ALT 27 IU/L, AST 30 IU/L, Cr 56 umol/L, BUN 4.8 mmol/L, IL-6 127 ng/L, TNF-α 355 (ng/L) At 24 h after treatment: Nasal discharge, Fever. At 48 h after treatment: Fever free, other symptoms remained. At 72 h after treatment all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.97×10⁹/L, ESR 15 mm/h, CRP 5.36 mg/L, ALT 37 IU/L, AST 25 IU/L, Cr 50 umol/L, BUN 3.2 mmol/L. IL-6 96 ng/L, TNF-α 214 ng/L. 16. Female, 11 months, 10 Kg, 76 cm. Nasal discharge, cough, Fever free. WBC count 9.55×10⁹/L, ESR 17 mm/h, CRP 5.25 mg/L, ALT 23 IU/L, AST 37 IU/L, Cr 85 umol/L, BUN 3.8 mmol/L, IL-6 87 ng/L, TNF-α 245 (ng/L) At 24 h after treatment: Fever free, cough and nasal discharge. At 48 h after treatment: all symptoms disappear. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.87×10⁹/L, ESR 15 mm/h, CRP 3.37 mg/L, ALT 25 IU/L, AST 30 IU/L, Cr 50 umol/L, BUN 4.2 mmol/L. IL-6 95 ng/L, TNF-α 217 ng/L. 17. Male, 1 year and 7 months, 13 Kg, 78 cm. Cough, Fever free, Pharyngitis, Tonsillitis. WBC count 11.75×10⁹/L, ESR 25 mm/h, CRP 7.55 mg/L, ALT 25 IU/L, AST 17 IU/L, Cr 66 umol/L, BUN 5.8 mmol/L, IL-6 1227 ng/L, TNF-α 365 (ng/L) At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 9.97×10⁹/L, ESR 17 mm/h, CRP 5.35 mg/L, ALT 37 IU/L, AST 25 IU/L, Cr 58 umol/L, BUN 3.5 mmol/L. IL-6 97 ng/L, TNF-α 235 ng/L. 18. Male, 1 year and 9 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.75×10⁹/L, ESR 19 mm/h, CRP 7.45 mg/L, ALT 33 IU/L, AST 38 IU/L, Cr 56 umol/L, BUN 4.1 mmol/L, IL-6 123 ng/L, TNF-α 355 (ng/L) At 24 h after treatment: Cough remained, Fever. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 8.81×10⁹/L, ESR 15 mm/h, CRP 7.35 mg/L, ALT 26 IU/L, AST 21 IU/L, Cr 59 umol/L, BUN 6.9 mmol/L. IL-6 96 ng/L, TNF-α 223 ng/L. 19. Female, 1 year and 4 months, 13 Kg, 76 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 9.96×10⁹/L, ESR 29 mm/h, CRP 9.97 mg/L, ALT 32 IU/L, AST 33 IU/L, Cr 66 umol/L, BUN 3.7 mmol/L, IL-6 135 ng/L, TNF-α 356 (ng/L) At 24 h after treatment: Cough, fever. At 48 h after treatment: Cough remained, Fever free. At 72 h after treatment: All symptoms disappeared. No vomiting, no diarrhea. WBC count 6.97×10⁹/L, ESR 16 mm/h, CRP 6.36 mg/L, ALT 36 IU/L, AST 33 IU/L, Cr 56 umol/L, BUN 6.6 mmol/L. IL-6 88 ng/L, TNF-α 236 ng/L. 20. Female, 10 years, 30 Kg, 148 cm. Cough, Nasal discharge, Fever free, WBC count 10.58×10⁹/L, ESR 25 mm/h, CRP 5.25 mg/L, ALT 20 IU/L, AST 18 IU/L, Cr 48 umol/L, BUN 2.3 mmol/L, IL-6 115 ng/L, TNF-α 345 (ng/L)

At 24 h after treatment: Cough, Nasal discharge, Fever free.

At 48 h after treatment: symptom disappeared At 72 h after treatment: No vomiting, no diarrhea. WBC count 7.08×10°/L, ESR 17 mm/h, CRP 7.63 mg/L, ALT 30 IU/L, AST 30 IU/L, Cr 42 umol/L, BUN 4.4 mmol/L. IL-6 83 ng/L, TNF-α 235 ng/L. 21. Female, 1 year and 9 months, 13 Kg, 76 cm. Nasal discharge, Pharyngitis, Tonsillitis, Fever free. WBC count 9.88×10⁹/L, ESR 20 mm/h, CRP 7.47 mg/L, ALT 23 IU/L, AST 38 IU/L, Cr 48 umol/L, BUN 3.8 mmol/L, IL-6 112 ng/L, TNF-α 341 (ng/L) At 24 h after treatment: Nasal discharge, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.59×10⁹/L, ESR 12 mm/h, CRP 6.56 mg/L, ALT 36 IU/L, AST 23 IU/L, Cr 49 umol/L, BUN 4.2 mmol/L. IL-6 95 ng/L, TNF-α 225 ng/L. 22. Female, 7 months, 8.5 Kg, 73 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.93×10⁹/L, ESR 37 mm/h, CRP 10.54 mg/L, ALT 24 IU/L, AST 25 IU/L, Cr 58 umol/L, BUN 6.1 mmol/L, IL-6 135 ng/L, TNF-α 397 (ng/L) At 24 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 11.65×10°/L, ESR 35 mm/h, CRP 9.36 mg/L, ALT 29 IU/L, AST38 IU/L, Cr 60 umol/L, BUN 5.2 mmol/L. IL-6 133 ng/L, TNF-α 405 ng/L. 23. Male, 8 months, 9.5 Kg, 74 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.36×10⁹/L, ESR 23 mm/h, CRP 8.74 mg/L, ALT 22 IU/L, AST 35 IU/L, Cr 63 umol/L, BUN 4.2 mmol/L, IL-6 122 ng/L, TNF-α 364 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: All symptoms disappeared. no vomiting, no diarrhea. WBC count 7.86×10⁹/L, ESR 18 mm/h, CRP 6.85 mg/L, ALT 34 IU/L, AST 23 IU/L, Cr 63 umol/L, BUN 6.1 mmol/L. IL-6 100 ng/L, TNF-α 231 ng/L. 24. Male, 2 years and 1 month, 14 Kg, 86 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 8.95×109/L, ESR 24 mm/h, CRP 9.44 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr 49 umol/L, BUN 3.3 mmol/L, IL-6 125 ng/L, TNF-α 386 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis. At 48 h after treatment: Cough, Fever free, Pharyngitis. At 72 h after treatment : All symptoms disappeared. No vomiting, no diarrhea. WBC count 7.98×10°/L, ESR 35 mm/h, CRP 6.36 mg/L, ALT 31 IU/L, AST 28 IU/L, Cr 44 umol/L, BUN 5.2 mmol/L. IL-6 81 ng/L, TNF-α 225 ng/L. 25. Male, 4 years, 16 Kg, 100 cm. Cough, Nasal discharge, Pharyngitis, Fever, Tonsillitis. WBC count 9.75×10⁹/L, ESR 20 mm/h, CRP 8.9 mg/L, ALT 20 IU/L, AST 30 IU/L, Cr 45 umol/L, BUN 3.8 mmol/L, IL-6 125 ng/L, TNF-α 355 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Cough, Nasal discharge, Fever free. At 72 h after treatment : all symptoms disappeared. No vomiting, no diarrhea. WBC count 6.45×10°/L, ESR 15 mm/h, CRP 7.37 mg/L, ALT 27 IU/L, AST 24 IU/L, Cr 68 umol/L, BUN 4.2 mmol/L. IL-6 90 ng/L, TNF-α 232 ng/L. 26. Female, 2 years and 2 months, 14 Kg, 87 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.35×10⁹/L, ESR 35 mm/h, CRP 30.28 mg/L, ALT 23 IU/L, AST 33 IU/L, Cr 53 umol/L, BUN 4.2 mmol/L, IL-6 139 ng/L, TNF-α 422 (ng/L) At 24 h after treatment: Nasal discharge, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Nasal discharge, Fever free, Pharyngitis, Tonsillitis. At 72 h after treatment: Nasal discharge, Fever free, Pharyngitis, Tonsillitis.

No vomiting, no diarrhea. WBC count 10.98×10^{9} /L, ESR 25 mm/h, CRP 8.36 mg/L, ALT 36 IU/L, AST 28 IU/L, Cr 55 umol/L, BUN 5.2 mmol/L. IL-6 145 ng/L, TNF- α 388 ng/L.

27. Female, 11 months, 10 Kg, 76 cm. Nasal discharge, Fever free, Pharyngitis, Tonsillitis.

WBC count 9.58×10⁹/L, ESR 38 mm/h, CRP 8.25 mg/L, ALT 23 IU/L, AST 36 IU/L, Cr 92 umol/L, BUN 6.8 mmol/L, IL-6 115 ng/L, TNF-α 356 (ng/L)

- At 24 h after treatment: Nasal discharge, Fever free.
- At 48 h after treatment: all symptoms disappeared.

At 72 h after treatment

No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 16 mm/h, CRP 7.35 mg/L, ALT 29 IU/L, AST 17 IU/L, Cr 47 umol/L, BUN 3.2 mmol/L. IL-6 97 ng/L, TNF- α 254 ng/L.

28. Male, 10 months, 9.5 Kg, 75 cm. Cough, Fever, Pharyngitis, Tonsillitis.

WBC count 11.76×10⁹/L, ESR 50 mm/h, CRP 30 mg/L, ALT 42 IU/L, AST 53 IU/L, Cr 60 umol/L, BUN 3.5 mmol/L, IL-6 138 ng/L, TNF-α 399 (ng/L)

At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.

At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.

At 72 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.

No vomiting, no diarrhea. WBC count 10.98×10^9 /L, ESR 35 mm/h, CRP 28.35 mg/L, ALT 35 IU/L, AST 20 IU/L, Cr 57 umol/L, BUN 3.2 mmol/L. IL-6 135 ng/L, TNF- α 415 ng/L.

- 29. Female, 3 years and 2 months, 16 Kg, 95 cm. Cough, Nasal discharge, Pharyngitis, Fever, Tonsillitis. WBC count 9.35×10⁹/L, ESR 18 mm/h, CRP 7.85 mg/L, ALT 26 IU/L, AST 35 IU/L, Cr 56 umol/L, BUN 3.5 mmol/L, IL-6 125 ng/L, TNF-α 353 (ng/L)
 - At 24 h after treatment: Cough, Fever.
 - At 48 h after treatment: Cough, Fever free.

At 72 h after treatment: all symptoms disappeared.

No vomiting, no diarrhea. WBC count 7.36×10⁹/L, ESR 16 mm/h, CRP 6.36 mg/L, ALT 36 IU/L, AST 28 IU/L, Cr 46 umol/L, BUN 6.2 mmol/L. IL-6 96 ng/L, TNF- α 265 ng/L.

30. Male, 7 years, 25 Kg, 122 cm. Cough, Nasal discharge, Fever free, Tonsillitis.
WBC count 9.51×10⁹/L, ESR 19 mm/h, CRP 4.68 mg/L, ALT 20 IU/L, AST 22 IU/L, Cr 62 umol/L, BUN 3.5 mmol/L, IL-6 157 ng/L, TNF-α 390 (ng/L)
At 24 h after treatment: Cough, Nasal discharge, Fever free.
At 48 h after treatment: all symptoms disappeared.
At 72 h after treatment

No vomiting, no diarrhea. WBC count 5.98×10⁹/L, ESR 15 mm/h, CRP 5.36 mg/L, ALT 35 IU/L, AST 28 IU/L, Cr 55 umol/L, BUN 5.1 mmol/L. IL-6 89 ng/L, TNF- α 225 ng/L.

- 31. Male, 1 year and 7 month, 12 Kg, 80 cm. Cough, Fever, Tonsillitis.
 WBC count 6.78×10⁹/L, ESR 25 mm/h, CRP 4.25 mg/L, ALT 26 IU/L, AST 16 IU/L, Cr 63 umol/L, BUN 3.2 mmol/L, IL-6 148 ng/L, TNF-α 349 (ng/L) At 24 h after treatment: Cough, Fever.
 - At 48 h after treatment: Cough, Fever free.
 - At 72 h after treatment: all symptoms disappeared.

No vomiting, no diarrhea. WBC count 8.58×10^9 /L, ESR 15 mm/h, CRP 5.36 mg/L, ALT 35 IU/L, AST 20 IU/L, Cr 55 umol/L, BUN 5.2 mmol/L. IL-6 157 ng/L, TNF- α 255 ng/L.

- 32. Female, 1 year and 5 months, 11.5 Kg, 78 cm. Nasal discharge, Pharyngitis, Fever, Tonsillitis . WBC count 9.68×10⁹/L, ESR 25 mm/h, CRP 3.75 mg/L, ALT 30 IU/L, AST 35 IU/L, Cr 62 umol/L, BUN 5.4 mmol/L, IL-6 123 ng/L, TNF-α 395 (ng/L)
 - At 24 h after treatment: Nasal discharge, Pharyngitis, Fever.
 - At 48 h after treatment: Nasal discharge, Fever free.
 - At 72 h after treatment : all symptoms disappeared.
 - At 72 h after treatment

No vomiting, no diarrhea. WBC count 6.52×10^{9} /L, ESR 16 mm/h, CRP 5. 63 mg/L, ALT 35 IU/L, AST 25 IU/L, Cr 55 umol/L, BUN 4.5 mmol/L. IL-6 99 ng/L, TNF- α 279 ng/L.

- 33. Male, 10 months, 9.5 Kg, 75 cm. Cough, Fever, Pharyngitis, Nasal discharge, Tonsillitis.
 WBC count 11.76×10⁹/L, ESR 50 mm/h, CRP 30 mg/L, ALT 42 IU/L, AST 50 IU/L, Cr 53 umol/L, BUN 3.5 mmol/L, IL-6 136 ng/L, TNF-α 402 (ng/L)
 At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
 - At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
 - At 48 h after treatment: all symptoms disappeared.
 - At 72 h after treatment : all symptoms disappeared.

No vomiting, no diarrhea. WBC count 9.98×10⁹/L, ESR 30 mm/h, CRP 9.36 mg/L, ALT 32 IU/L, AST 22 IU/L, Cr 47 umol/L, BUN 4.2 mmol/L. IL-6 114 ng/L, TNF-α 411 ng/L. 34. Female, 4 years and 3 months, 20 Kg, 110 cm. Cough, Pharyngitis, Fever, Tonsillitis. WBC count 9.35×10⁹/L, ESR 18 mm/h, CRP 7.83 mg/L, ALT 26 IU/L, AST 33 IU/L, Cr 65 umol/L, BUN 3.3 mmol/L, IL-6 124 ng/L, TNF-α 353 (ng/L) At 24 h after treatment: Cough, Fever. At 48 h after treatment: all symptoms disappeared. At 72 h after treatment : all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.35×10⁹/L, ESR 10 mm/h, CRP 6.35 mg/L, ALT 35 IU/L, AST 28 IU/L, Cr 47 umol/L, BUN 6.2 mmol/L. IL-6 98 ng/L, TNF-α 255 ng/L. 35. Male, 9 years, 28 Kg, 140 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 10.35×10⁹/L, ESR 26 mm/h, CRP 4.76 mg/L, ALT 25 IU/L, AST 25 IU/L, Cr 55 umol/L, BUN 3.7 mmol/L, IL-6 135 ng/L, TNF-α 407 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Cough, Nasal discharge, Fever free. At 72 h after treatment : all symptoms disappeared. No vomiting, no diarrhea. WBC count 6.55×10⁹/L, ESR 8 mm/h, CRP 6.46 mg/L, ALT 34 IU/L, AST 30 IU/L, Cr 77 umol/L, BUN 4.3 mmol/L. IL-6 93 ng/L, TNF-α 253 ng/L. 36. Male, 9 years, 32 Kg, 145 cm. Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 9.76×10°/L, ESR 16 mm/h, CRP 5.6 mg/L, ALT 35 IU/L, AST 35 IU/L, Cr 55 umol/L, BUN 3.5 mmol/L, IL-6 155 ng/L, TNF-α 366 (ng/L) At 24 h after treatment: Nasal discharge, Pharyngitis, Tonsillitis, Fever. At 48 h after treatment: Nasal discharge, Fever free. At 72 h after treatment : all symptoms disappeared. No vomiting, no diarrhea. WBC count 5.65×10⁹/L, ESR 13 mm/h, CRP 4.98 mg/L, ALT 22 IU/L, AST 29 IU/L, Cr 55 umol/L, BUN 4.8 mmol/L. IL-6 95 ng/L, TNF-α 275 ng/L. 37. Female, 11 years, 35 Kg, 150 cm. Cough, Nasal discharge, Pharyngitis, Fever free, Tonsillitis. WBC count 5.58×10⁹/L, ESR 15 mm/h, CRP 4.35 mg/L, ALT 21 IU/L, AST 37 IU/L, Cr 62 umol/L, BUN 3.8 mmol/L, IL-6 145 ng/L, TNF-α 399 (ng/L) At 24 h after treatment: Cough remained, Fever free. At 48 h after treatment: All symptoms disappeared. At 72 h after treatment No vomiting, no diarrhea. WBC count 6.45×10⁹/L, ESR 10 mm/h, CRP 3.65 mg/L, ALT 30 IU/L, AST 28 IU/L, Cr 63 umol/L, BUN 3.2 mmol/L. IL-6 90 ng/L, TNF-α 305 ng/L. 38. Female, 6 years, 15 Kg, 103 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 12.83×10⁹/L, ESR 39 mm/h, CRP 10.25 mg/L, ALT 20 IU/L, AST 35 IU/L, Cr 52 umol/L, BUN 3.9 mmol/L, IL-6 187 ng/L, TNF-α 399 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: all symptoms disappeared. No vomiting, no diarrhea. WBC count 11.35×10⁹/L, ESR 33 mm/h, CRP 8.34 mg/L, ALT 35 IU/L, AST 28 IU/L, Cr 64 umol/L, BUN 5.6 mmol/L. IL-6 97 ng/L, TNF-α 245 ng/L. 39. Male, 8 years, 27 Kg, 112 cm. Fever, Pharyngitis, Tonsillitis. WBC count 15.95×10⁹/L, ESR 50 mm/h, CRP 28.55 mg/L, ALT 38 IU/L, AST 42 IU/L, Cr 66 umol/L, BUN 4.8 mmol/L, IL-6 135 ng/L, TNF-α 418 (ng/L) At 24 h after treatment: Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: Fever, Pharyngitis, Tonsillitis. No vomiting, no diarrhea. WBC count 14.68×10⁹/L, ESR 45 mm/h, CRP 22.36 mg/L, ALT 30 IU/L, AST 32 IU/L, Cr 49 umol/L, BUN 5.1 mmol/L. IL-6 135 ng/L, TNF-α 320 ng/L. 40. Male, 11 month, 10.5 Kg, 78 cm. Cough, Fever, Pharyngitis, Tonsillitis.

WBC count 12.98×10⁹/L, ESR 38 mm/h, CRP 20.45 mg/L, ALT 40 IU/L, AST 32 IU/L, Cr 58 umol/L, BUN 5.5 mmol/L, IL-6 133 ng/L, TNF- α 429 (ng/L)

At 24 h after treatment: Cough, Fever, Tonsillitis.

Protective effects of traditional Chinese medicine on children with respiratory

At 48 h after treatment: Cough, Fever, Tonsillitis.

At 72 h after treatment: all symptoms disappeared.

No vomiting, no diarrhea. WBC count 10.38×10⁹/L, ESR 25 mm/h, CRP 12.52 mg/L, ALT 32 IU/L, AST 26 IU/L, Cr 61 umol/L, BUN 5.2 mmol/L. IL-6 122 ng/L, TNF- α 312 ng/L.

- 41. Female, 6 years, 123 Kg, 116 cm. Cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis. WBC count 7.25×10^{9} /L, ESR 25mm/h, CRP 7.55 mg/L, ALT 36 IU/L, AST 33 IU/L, Cr 53 umol/L, BUN 5.7 mmol/L, IL-6 133 ng/L, TNF- α 396 (ng/L) At 24 h after treatment: Cough, Nasal discharge, Pharyngitis, Fever. At 48 h after treatment: Cough, Nasal discharge, Fever free. At 72 h after treatment : all symptoms disappeared. No vomiting, no diarrhea. WBC count 7.98×10⁹/L, ESR 18 mm/h, CRP 6.37 mg/L, ALT 37 IU/L, AST 22 IU/L, Cr 55 umol/L, BUN 4.2 mmol/L. IL-6 92 ng/L, TNF- α 275 ng/L.
- 42. Male, 11 months, 10 Kg, 76 cm. Fever, Pharyngitis, Tonsillitis.
 WBC count 9.77×10⁹/L, ESR 37 mm/h, CRP 17.75 mg/L, ALT 35 IU/L, AST 30 IU/L, Cr 56 umol/L, BUN 5.5 mmol/L, IL-6 143 ng/L, TNF-α 417 (ng/L)
 At 24 h after treatment: Fever, Pharyngitis, Tonsillitis.
 At 48 h after treatment: Fever free, Pharyngitis, Tonsillitis.
 At 72 h after treatment: Fever free, Pharyngitis, Tonsillitis.
 No vomiting, no diarrhea. WBC count 8.98×10⁹/L, ESR 30 mm/h, CRP 15.26 mg/L, ALT 37 IU/L, AST 30 IU/L, Cr 59 umol/L, BUN 6.5 mmol/L. IL-6 125 ng/L, TNF-α 415 ng/L.
- 43. Male, 1 year and 2 months, 11 Kg, 79 cm. Cough, Fever, Pharyngitis, Tonsillitis.
 WBC count 3.58×10⁹/L, ESR 33 mm/h, CRP 20.49 mg/L, ALT 39 IU/L, AST 33 IU/L, Cr 60 umol/L, BUN 5.0 mmol/L, IL-6 121 ng/L, TNF-α 412 (ng/L)
 At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
 At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis.
 At 72 h after treatment: all symptoms disappeared.
 No vomiting, no diarrhea. WBC count 7.99×10⁹/L, ESR 21 mm/h, CRP 9.36 mg/L, ALT 30 IU/L, AST 32 IU/L, Cr 63 umol/L, BUN 4.9 mmol/L. IL-6 136 ng/L, TNF-α 362 ng/L.
- 44. Male, 1 year and 9 months, 10 Kg, 76 cm. Cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis. WBC count 8.97×10⁹/L, ESR 18 mm/h, CRP 7.45 mg/L, ALT 23 IU/L, AST 38 IU/L, Cr 67 umol/L, BUN 5.8 mmol/L, IL-6 128 ng/L, TNF-α 335 (ng/L)
 - At 24 h after treatment: Cough remained, Fever free.
 - At 48 h after treatment: All symptoms disappeared.
 - At 72 h after treatment

No vomiting, no diarrhea. WBC count 7.75×10^9 /L, ESR 17 mm/h, CRP 7.30 mg/L, ALT 30 IU/L, AST 20 IU/L, Cr 50 umol/L, BUN 4.2 mmol/L. IL-6 85 ng/L, TNF- α 223 ng/L.

45. Male, 1 year and 5 months, 13 Kg, 77 cm. Cough, Fever, Pharyngitis, Tonsillitis. WBC count 4.06×10⁹/L, ESR 42 mm/h, CRP 18.45 mg/L, ALT 32 IU/L, AST 26 IU/L, Cr 54 umol/L, BUN 6.7 mmol/L, IL-6 105 ng/L, TNF-α 359 (ng/L) At 24 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 48 h after treatment: Cough, Fever, Pharyngitis, Tonsillitis. At 72 h after treatment: all symptoms disappeared.

No vomiting, no diarrhea. WBC count 10.33×10⁹/L, ESR 25 mm/h, CRP 9.35 mg/L, ALT 21 IU/L, AST 27 IU/L, Cr 40 umol/L, BUN 6.5 mmol/L. IL-6 139 ng/L, TNF- α 305 ng/L.

46. Female, 3 years, 15 Kg, 95 cm. Cough, Nasal discharge, fever free.
WBC count 9.26×10⁹/L, ESR 15 mm/h, CRP 5.45 mg/L, ALT 25 IU/L, AST 34 IU/L, Cr 60 umol/L, BUN 4.8 mmol/L, IL-6 113 ng/L, TNF-α 335 (ng/L)
At 24 h after treatment: Cough, Nasal discharge fever free.
At 48 h after treatment: Fever free, Cough, Nasal discharge.
At 72 h after treatment : symptoms disappeared
No vomiting, no diarrhea. WBC count 7.85×10⁹/L, ESR 15 mm/h, CRP 4.35 mg/L, ALT 15 IU/L, AST 20 IU/L, Cr 67 umol/L, BUN 5.2 mmol/L. IL-6 115 ng/L, TNF-α 269 ng/L.

47. Male, 1 year and 10 months, 13.5 Kg, 80 cm. cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.

WBC count 4. 85×10⁹/L, ESR 52 mm/h, CRP 28 mg/L, ALT 40 IU/L, AST 50 IU/L, Cr 56 umol/L, BUN 5.8 mmol/L, IL-6 137 ng/L, TNF-α 416 (ng/L)

At 24 h after treatment: cough, Nasal discharge, Fever, Pharyngitis, Tonsillitis.

At 48 h after treatment: cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis.

At 72 h after treatment: cough, Nasal discharge, Fever free, Pharyngitis, Tonsillitis.

No vomiting, no diarrhea. WBC count 9. 95×10^9 /L, ESR 35 mm/h, CRP 25 mg/L, ALT 30 IU/L, AST 29 IU/L, Cr 55 umol/L, BUN 4.9 mmol/L. IL-6 120 ng/L, TNF- α 397 ng/L.

48. Female, 3 years and 4 months, 16 Kg, 96 cm. Cough, Pharyngitis, Fever, Tonsillitis.

WBC count 9.35×10^{9} /L, ESR 22 mm/h, CRP 8.86 mg/L, ALT 26 IU/L, AST 33 IU/L, Cr 52 umol/L, BUN 3.3 mmol/L, IL-6 127 ng/L, TNF- α 359 (ng/L)

At 24 h after treatment: Cough, Fever.

At 48 h after treatment: All symptoms disappeared.

At 72 h after treatment : all symptoms disappeared.

No vomiting, no diarrhea. WBC count 7.31×10⁹/L, ESR 10 mm/h, CRP 6.42 mg/L, ALT 30 IU/L, AST 28 IU/L, Cr 55 umol/L, BUN 6.2 mmol/L. IL-6 105 ng/L, TNF- α 235 ng/L.

49. Male, 1 year and 9 months, 13 Kg, 80 cm. Nasal discharge, Fever, Tonsillitis.

WBC count 4. 85×10⁹/L, ESR 33 mm/h, CRP 10 mg/L, ALT 42 IU/L, AST 53 IU/L, Cr 55 umol/L, BUN 5.8 mmol/L, IL-6 95 ng/L, TNF- α 364 (ng/L)

At 24 h after treatment: Nasal discharge, Fever, Tonsillitis.

At 48 h after treatment: All symptoms disappeared.

At 72 h after treatment: All symptoms disappeared.

No vomiting, no diarrhea. WBC count 9.89×10^9 /L, ESR 23 mm/h, CRP 7.3 mg/L, ALT 31 IU/L, AST 29 IU/L, Cr 59 umol/L, BUN 5.2 mmol/L. IL-6 135 ng/L, TNF- α 367 ng/L.